No Data
China Resources Pharmaceutical Group to Renew Cooperation Agreements
CHINARES PHARMA (03320.HK) has signed a strategic cooperation agreement with Banks for 2025.
On December 31, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that on December 31, 2024, the company entered into a 2025 strategic cooperation agreement with CHINARES Banks and a 2025 strategic cooperation agreement with CHINARES REITs, effective from January 1, 2025, and ending on December 31, 2027.
CHINARES PHARMA (03320.HK) signed a procurement framework agreement for Information Technology Services with CHINARES Digital.
On December 30, Gelonghui reported that CHINARES PHARMA (03320.HK) announced that on December 30, 2024, the company signed a procurement framework agreement for Information Technology Services with CHINA RESOURCES Digital, whereby the group has agreed to purchase Information Technology Services from CHINA RESOURCES Digital Group, with a term starting from January 1, 2025, to December 31, 2027.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Zhejiang Zhenyuan Share (000705.SZ) plans to sign the "Capital Increase Agreement" with CHINARES PHARMA.
On December 24th, Gelonghui reported that Zhejiang Zhenyuan Share (000705.SZ) announced that it has carried out a capital increase by introducing strategic investors for its wholly-owned subsidiary, Shaoxing Zhenyuan Pharmaceutical Operation Co., Ltd. (referred to as "Zhenyuan Pharmaceuticals"), through a public listing at the Shaoxing Property Exchange. After review by the exchange and confirmation by the company, CHINARES PHARMA was determined to be the qualified investor for the capital increase, and a "Capital Increase Agreement" is planned to be signed with CHINARES PHARMA at a price of 1.439517 yuan per registered capital, with an increase amount of 119.8618235 million yuan.
CHINARES PHARMA (03320.HK): Completed the proposed internal restructuring involving China Resources Shengkai.
On December 20, Gelonghui reported that CHINARES PHARMA (03320.HK) announced a proposed internal restructuring involving its non-wholly owned subsidiary, Kunming CHINARES Shenghuo Pharmaceutical Co., Ltd. ("CHINARES Shenghuo"). On December 20, 2024, according to the terms of the Equity Transfer Agreement, China Resources Sanjiu Medical & Pharmaceutical proposed to transfer 51% equity in CHINARES Shenghuo to Kunming Pharmaceutical. The trade has completed business registration, and the transfer has been finalized.
No Data
